For an injectable medicine, the molecule is only half the product. The other half is the device that gets it into the patient — and as more biologics move to self-administration at home, the auto-injector has become a competitive surface in its own right. The companies that make injectable franchises file heavily on that hardware, because device patents protect how a drug is delivered even when the molecule's own protection is a separate question. The first week of April 2026 produced a grant that shows how deep Sanofi's coverage on that hardware runs.

On 31 March 2026, the U.S. patent office granted US12589207B2, titled "Auto-injector." The claimed invention is the internal mechanism that performs the whole injection sequence from a single spring. The abstract describes it step by step:

A spring capable of, upon activation: pushing the needle from a covered position inside the housing into an advanced position through the orifice and past the proximal end (P), operating the syringe to supply the dose of medicament (M), and retracting the syringe with the needle into the covered position.— Auto-injector, US12589207B2

The grant's CPC classifications sit entirely in the A61M injection-device classes — A61M 5/2033 and A61M 5/3232 for the auto-injector and needle-shielding mechanics, A61M 5/3202 for the safety arrangement. There is no chemistry or formulation class on the record; this is a pure device patent, coverage on the mechanism rather than on anything it delivers. The claims reach to construction detail, including that the needle-shielding sleeve "is a monolithic structure." For a business reader, the relevance is that it is one more issued tile in a device estate that is unusually large.

The grant sits inside a very deep device estate

What makes this a coverage map is the sheer footprint around it. Sanofi's device unit holds a large number of issued injection-device patents in the public patent record, and they span every sub-component of the hardware. On the safety side, US10512733B2 and US10471220B2 both cover safety devices for prefilled syringes — the shields and sleeves that lock a needle away after use. On user-feedback features, US10518041B2 covers a releasable noise component that signals the end of an injection, and US10471217B2 covers an end-of-dispense feedback feature — coverage on the click-and-confirm cues that matter for at-home dosing.

The estate also reaches into reusable pen injectors and the electronics being layered onto them. US10512732B2 covers a dose-knob clutch that prevents dosing inaccuracies on a dial-a-dose pen, and US10471216B2 covers an apparatus for recording the amount of medicament ejected — the connected-device direction that turns an injection pen into a data-logging tool. Spring-driven auto-injectors, safety shields, audible feedback, pen-injector clutches, dose-recording electronics: the issued footprint reads as layered coverage across the entire injection-device, with the new auto-injector grant adding another mechanism tile.

The volume is the headline figure. The public patent record attributes well over a thousand grants to Sanofi's device unit, with annual issued-grant counts running into the dozens and CPC concentration overwhelmingly in the A61M 5 injection classes — A61M 5/24, A61M 5/2033, A61M 5/3202, A61M 5/326 each appearing on hundreds of records. A device estate of that depth is what a company assembles when the delivery hardware is treated as a product line of its own, not an afterthought to the drug. Reading the classification mix, the older grants concentrate on the purely mechanical components, while a visible slice of the more recent filings carry electronic and dose-tracking classes — indicating the device program is extending toward connected, data-capturing injectors.

It is worth being concrete about why a drugmaker accumulates a device estate this size. Many injectable products — insulins, anticoagulants, and a growing list of self-administered biologics — reach the patient not through a vial and a separate syringe but through a single integrated device the patient operates unaided. The device determines whether the right dose is delivered, whether the needle is ever seen, and whether the user gets confirmation the injection finished. Each of those functions is a separate engineering problem, and each is separately patentable, which is why a single injectable franchise can sit behind dozens of distinct device grants. The April auto-injector patent is one such function — the actuation sequence — captured as its own claim.

What the issued coverage buys

The business significance of a coverage map this dense is in freedom-to-operate on the device. A granted claim is the enforceable part of an estate, and Sanofi holds issued claims across nearly every functional element of an auto-injector or pen — the actuation spring, the needle shield, the feedback click, the dose mechanism. A competitor or a biosimilar developer that needs an at-home injection device for its own product has to design around a wall of issued device claims, which is the kind of pressure that surfaces as device-licensing deals, contract-manufacturing arrangements, or design-arounds rather than in any single headline. The 31 March 2026 grant shows the company still issuing new mechanism coverage on top of an already-deep base.

The usual caveats apply. Issued claims describe what was granted, not how broadly a court would construe them or whether any survives a validity challenge, and the older grants reflect filings made years ago whose terms run on their own clocks. Injection devices also have other large suppliers and contract device makers filing comparable hardware patents, so this footprint maps one company's positions rather than the whole field. But the pattern across Sanofi's issued device patents is unambiguous: broad, sustained coverage on the hardware that delivers an injectable drug, component by component. The April grant is the newest tile in that map, and it sits on the core mechanism — the spring that does the injection.